.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,173,690

« Back to Dashboard

Details for Patent: 8,173,690

Title:Compounds, compositions and methods of using same for modulating uric acid levels
Abstract: Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of making and using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.
Inventor(s): Gunic; Esmir (San Diego, CA), Girardet; Jean-Luc (San Diego, CA), Vernier; Jean-Michel (San Diego, CA), Tedder; Martina E. (Capistrano Beach, CA), Paisner; David A. (Encinltas, CA)
Assignee: Ardea Biosciences, Inc. (San Diego, CA)
Filing Date:Sep 03, 2009
Application Number:12/553,844
Claims:1. A compound having the following structure: ##STR00198## or a pharmaceutically acceptable salt, ester, or tautomer thereof, wherein: W is O or S; R.sup.1 is H, F, Cl, Br, I, --CH.sub.2F, --CF.sub.2H, --CF.sub.3, --CN, --OH, --NO.sub.2, --NH.sub.2, --NH(C.sub.1-4alkyl), --N(C.sub.1-4alkyl)(C.sub.1-4alkyl), --SO.sub.2CH.sub.3, --SO.sub.2NH.sub.2, --SO.sub.2NHCH.sub.3, --CO.sub.2--C.sub.1-4alkyl, C.sub.1-4alkyl, C.sub.1-4alkenyl, C.sub.1-4alkoxy, C.sub.1-4S-alkyl, C.sub.3-6cycloalkyl, optionally substituted C.sub.1-6heterocycloalkyl, optionally substituted phenyl, or optionally substituted 5 or 6 membered heteroaryl; R.sup.d is F, Cl, Br, I, CF.sub.3, aryl, heteroaryl, CN, NO.sub.2, NH.sub.2, NHR', OH, OR', SH, SR', C(O)R', CO.sub.2H, COOR', CONH.sub.2, CONHR', CONR'R'', SO.sub.3H, SO.sub.3R', S(O).sub.2R', S(O).sub.2NH.sub.2, S(O).sub.2NHR', or S(O).sub.2NR'R''; R.sup.d1 is zero to four substituents independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heteroalkyl, optionally substituted heteroalkenyl, optionally substituted heteroalkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, halo, CN, NH.sub.2, NHR', NR'R'', OH, OR', SH, SR', C(O)R', CO.sub.2H, COOR', CONH.sub.2, CONHR', CONR'R'', SO.sub.3H, S(O).sub.2R', S(O).sub.2NH.sub.2, S(O).sub.2NHR', or S(O).sub.2NR'R''; each R' is independently methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl or phenyl; each R'' is independently methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl or phenyl; or R' and R'' are together with the atom to which they are attached form an optionally substituted, saturated or unsaturated 4-, 5- or 6-membered ring; R.sup.x and R.sup.x' are each independently H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heteroalkyl, optionally substituted heteroalkenyl, optionally substituted heteroalkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, halo, CN, NH.sub.2, NHR', NR'R'', OH, OR', SH, SR', C(O)R', CO.sub.2H, COOR', CONH.sub.2, CONHR', CONR'R'', SO.sub.3H, S(O).sub.2R', S(O).sub.2NH.sub.2, S(O).sub.2NHR', or S(O).sub.2NR'R''; or R.sup.x and R.sup.x' together with the carbon atom to which they are attached, form an optionally substituted non-aromatic 3-7 membered ring, optionally comprising 1 or 2 heteroatoms selected from O, N and S; B.sup.3 is OB.sup.1, NB.sup.2.sub.2, or an amino acid residue or an alkyl ester thereof; B.sup.1 is H, optionally substituted C.sub.1-6 alkyl or a pharmaceutically acceptable cation; and each B.sup.2 is independently H or optionally substituted alkyl.

2. The compound of claim 1, wherein W is S.

3. The compound of claim 1, wherein W is O.

4. The compound of claim 1, wherein B.sup.3 is OB.sup.1.

5. The compound of claim 1, wherein B.sup.1 is an alkali earth metal cation or an alkaline earth metal cation.

6. The compound of claim 1, wherein B.sup.3 is NB.sup.2.sub.2.

7. The compound of claim 1 wherein B.sup.3 is an amino acid residue or lower alkyl ester thereof.

8. The compound of claim 1, wherein R.sup.x and R.sup.x' are independently H, F, CF.sub.3, or methyl.

9. The compound of claim 1, wherein R.sup.x is F and R.sup.x1 is F.

10. The compound of claim 1, wherein R.sup.1 is H, F, Cl, Br, CH.sub.2F, CF.sub.2H, CF.sub.3, NH.sub.2, or CH.sub.3.

11. The compound of claim 1, wherein R.sup.1 is Br.

12. The compound of claim 1, wherein R.sup.d is H, F, Cl, Br, I, CF.sub.3, or CN.

13. A compound having the following structure: ##STR00199## or a pharmaceutically acceptable salt, ester, or tautomer thereof, wherein: W is O or S; R.sup.1 is H, F, Cl, Br, I, --CH.sub.2F, --CF.sub.2H, --CF.sub.3, --CN, --OH, --NO.sub.2, --NH.sub.2, --NH(C.sub.1-4alkyl), --N(C.sub.1-4alkyl)(C.sub.1-4alkyl), --SO.sub.2CH.sub.3, --SO.sub.2NH.sub.2, --SO.sub.2NHCH.sub.3, --CO.sub.2--C.sub.1-4alkyl, C.sub.1-4alkyl, C.sub.1-4alkenyl, C.sub.1-4alkoxy, C.sub.1-4S-alkyl, C.sub.3-6cycloalkyl, optionally substituted C.sub.1-6heterocycloalkyl, optionally substituted phenyl, or optionally substituted 5 or 6 membered heteroaryl; R.sup.d is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heteroalkyl, optionally substituted heteroalkenyl, optionally substituted heteroalkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, halo, CN, NO.sub.2, NH.sub.2, NHR', NR'R'', OH, OR', SH, SR', C(O)R', CO.sub.2H, COOR', CONH.sub.2, CONHR', CONR'R'', SO.sub.3H, SO.sub.3R', S(O).sub.2R', S(O).sub.2NH.sub.2, S(O).sub.2NHR', or S(O).sub.2NR'R''; R.sup.d1 is zero to four substituents independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heteroalkyl, optionally substituted heteroalkenyl, optionally substituted heteroalkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, halo, CN, NH.sub.2, NHR', NR'R'', OH, OR', SH, SR', C(O)R', CO.sub.2H, COOR', CONH.sub.2, CONHR', CONR'R'', SO.sub.3H, S(O).sub.2R', S(O).sub.2NH.sub.2, S(O).sub.2NHR', or S(O).sub.2NR'R''; each R' is independently methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl or phenyl; each R'' is independently methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl or phenyl; or R' and R'' are together with the atom to which they are attached form an optionally substituted, saturated or unsaturated 4-, 5- or 6-membered ring; R.sup.x is F, Cl, Br, I, or C.sub.1-C.sub.3 fluoroalkyl; R.sup.x' is independently H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heteroalkyl, optionally substituted heteroalkenyl, optionally substituted heteroalkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, halo, CN, NH.sub.2, NHR', NR'R'', OH, OR', SH, SR', C(O)R', CO.sub.2H, COOR', CONH.sub.2, CONHR', CONR'R'', SO.sub.3H, S(O).sub.2R', S(O).sub.2NH.sub.2, S(O).sub.2NHR', or S(O).sub.2NR'R''; and B.sup.3 is OB.sup.1, NB.sup.2.sub.2, or an amino acid residue or an alkyl ester thereof; B' is H, optionally substituted C.sub.1-6 alkyl or a pharmaceutically acceptable cation; and each B.sup.2 is independently H or optionally substituted alkyl.

14. The compound of claim 13, wherein W is S.

15. The compound of claim 13, wherein W is O.

16. The compound of claim 13, wherein B.sup.3 is OB.sup.1.

17. The compound of claim 13, wherein B.sup.1 is an alkali earth metal cation or an alkaline earth metal cation.

18. The compound of claim 13, wherein B.sup.3 is NB.sup.2.sub.2.

19. The compound of claim 13 wherein B.sup.3 is an amino acid residue or lower alkyl ester thereof.

20. The compound of claim 13, wherein R.sup.x and R.sup.x' are independently H, F, methyl, or CF.sub.3.

21. The compound of claim 13, wherein R.sup.x is F and R.sup.x1 is F.

22. The compound of claim 13, wherein R.sup.1 is H, F, Cl, Br, CH.sub.2F, CF.sub.2H, CF.sub.3, NH.sub.2, or CH.sub.3.

23. The compound of claim 13, wherein R.sup.1 is Br.

24. The compound of claim 13, wherein R.sup.d is F, Cl, Br, I, CF.sub.3, or CN.

25. A compound having the following structure: ##STR00200## or a pharmaceutically acceptable salt, ester, or tautomer thereof, wherein: W is O or S; R.sup.1 is halo; R.sup.d is H; R.sup.d1 is zero to four substituents independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heteroalkyl, optionally substituted heteroalkenyl, optionally substituted heteroalkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, halo, CN, NH.sub.2, NHR', NR'R'', OH, OR', SH, SR', C(O)R', CO.sub.2H, COOR', CONH.sub.2, CONHR', CONR'R'', SO.sub.3H, S(O).sub.2R', S(O).sub.2NH.sub.2, S(O).sub.2NHR', or S(O).sub.2NR'R''; each R' is independently methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl or phenyl; each R'' is independently methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl or phenyl; or R' and R'' are together with the atom to which they are attached form an optionally substituted, saturated or unsaturated 4-, 5- or 6-membered ring; R.sup.x and R.sup.x' are each independently H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heteroalkyl, optionally substituted heteroalkenyl, optionally substituted heteroalkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, halo, CN, NH.sub.2, NHR', NR'R'', OH, OR', SH, SR', C(O)R', CO.sub.2H, COOR', CONH.sub.2, CONHR', CONR'R'', SO.sub.3H, S(O).sub.2R', S(O).sub.2NH.sub.2, S(O).sub.2NHR', or S(O).sub.2NR'R''; or R.sup.x and R.sup.x' together with the carbon atom to which they are attached, form an optionally substituted non-aromatic 3-7 membered ring, optionally comprising 1 or 2 heteroatoms selected from O, N and S; B.sup.3 is OB.sup.1, NB.sup.2.sub.2, or an amino acid residue or an alkyl ester thereof; B.sup.1 is H, optionally substituted C.sub.1-6 alkyl or a pharmaceutically acceptable cation; and each B.sup.2 is independently H or optionally substituted alkyl.

26. The compound of claim 25, wherein W is S.

27. The compound of claim 25, wherein W is O.

28. The compound of claim 25, wherein B.sup.3 is OB.sup.1.

29. The compound of claim 25, wherein B.sup.1 is an alkali earth metal cation or an alkaline earth metal cation.

30. The compound of claim 25, wherein B.sup.3 is NB.sup.2.sub.2.

31. The compound of claim 25, wherein B.sup.3 is an amino acid residue or lower alkyl ester thereof.

32. The compound of claim 25, wherein R.sup.x and R.sup.x1 are independently H, F, CF.sub.3, or methyl.

33. The compound of claim 25, wherein R.sup.x is methyl and R.sup.x1 is methyl.

34. A method of treating gout comprising administering to an individual in need thereof a therapeutically effective amount of a compound of any of claim 1, 13 or 25.

35. A method of treating hyperuricemia comprising administering to an individual in need thereof a therapeutically effective amount of a compound of any of claim 1, 13 or 25.

36. A pharmaceutical composition comprising a therapeutically effective amount of a compound of any of claim 1, 13 or 25 and a pharmaceutically acceptable excipient.

37. The pharmaceutical composition of claim 36, wherein the therapeutically effective amount of the compound is an amount therapeutically effective for treating gout.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc